Esperion Therapeutics (ESPR) Trading 8.5% Higher
Esperion Therapeutics Inc (NASDAQ:ESPR) shares traded up 8.5% during mid-day trading on Tuesday . The company traded as high as $64.88 and last traded at $64.38. 846,539 shares were traded during trading, a decline of 16% from the average session volume of 1,003,047 shares. The stock had previously closed at $59.36.
A number of research analysts have issued reports on the stock. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Northland Securities reaffirmed a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Chardan Capital reaffirmed a “neutral” rating and set a $75.00 price target (up previously from $20.00) on shares of Esperion Therapeutics in a report on Tuesday, December 5th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $60.85.
The firm has a market cap of $1,660.00, a PE ratio of -9.38 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period in the prior year, the business posted ($0.77) EPS. research analysts forecast that Esperion Therapeutics Inc will post -7.3 EPS for the current year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 32.50% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Meditor Group Ltd increased its stake in shares of Esperion Therapeutics by 305.5% in the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares in the last quarter. BB Biotech AG grew its stake in Esperion Therapeutics by 7.5% during the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after acquiring an additional 105,000 shares in the last quarter. State Street Corp grew its stake in Esperion Therapeutics by 264.6% during the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after acquiring an additional 1,093,292 shares in the last quarter. FMR LLC grew its stake in Esperion Therapeutics by 2.3% during the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Discovery Capital Management LLC CT lifted its position in Esperion Therapeutics by 152.9% during the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after purchasing an additional 583,529 shares during the last quarter. Institutional investors and hedge funds own 92.24% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.